Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q1XV
|
|||
| Former ID |
DIB006954
|
|||
| Drug Name |
HBV vaccine
|
|||
| Synonyms |
HBV vaccine (adjuvanted); HBV vaccine (adjuvanted), GlaxoSmithKline Biologicals
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Hepatitis B virus infection [ICD-11: 1E51.0; ICD-10: B18.1] | Phase 2 | [1] | |
| Company |
GlaxoSmithKline Biologicals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cell mediated immunity response (CMIR) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01777295) Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT00508833) Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.